Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 15 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Hester Biosciences Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 15, 2024, 3:12 pm

Market Cap 2,090 Cr.
Current Price 2,457
High / Low3,379/1,293
Stock P/E89.0
Book Value 355
Dividend Yield0.24 %
ROCE9.32 %
ROE6.60 %
Face Value 10.0
PEG Ratio-10.20

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Hester Biosciences Ltd

Competitors of Hester Biosciences Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Industry Average0 Cr0000%0.59%0.49%0

All Competitor Stocks of Hester Biosciences Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales56.8964.1860.1962.6655.6956.4750.7073.1574.9467.3087.8570.4666.98
Expenses35.7144.4043.1245.1040.6646.1543.2760.4056.1855.6373.4957.2456.83
Operating Profit21.1819.7817.0717.5615.0310.327.4312.7518.7611.6714.3613.2210.15
OPM %37.23%30.82%28.36%28.02%26.99%18.28%14.65%17.43%25.03%17.34%16.35%18.76%15.15%
Other Income1.27-0.842.351.422.787.624.695.016.373.492.525.912.20
Interest1.521.440.860.740.961.501.602.463.891.372.578.082.19
Depreciation3.273.633.233.055.175.135.065.035.245.375.404.283.75
Profit before tax17.6613.8715.3315.1911.6811.315.4610.2716.008.428.916.776.41
Tax %27.12%27.18%28.11%26.73%28.68%20.34%34.98%35.74%24.00%32.19%24.69%40.18%37.44%
Net Profit12.8710.1011.0211.138.339.003.566.6012.165.716.714.044.02
EPS in Rs14.5211.3914.6812.489.979.074.678.1613.155.336.904.814.68

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales48656990101123136178183214235266293
Expenses30434464678289110128146175215243
Operating Profit19222425344147685569605149
OPM %39%34%36%28%34%33%35%38%30%32%26%19%17%
Other Income0013103761142014
Interest33654447774914
Depreciation44566710121313172119
Profit before tax12141318253136574150544031
Tax %37%37%31%26%23%26%36%28%25%31%26%30%
Net Profit79913192323413135392820
EPS in Rs8.9510.8911.1115.9922.5727.6830.1248.8734.2940.4746.2231.3021.72
Dividend Payout %7%18%18%19%18%19%33%23%19%25%22%26%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)28.57%0.00%44.44%46.15%21.05%0.00%78.26%-24.39%12.90%11.43%-28.21%
Change in YoY Net Profit Growth (%)0.00%-28.57%44.44%1.71%-25.10%-21.05%78.26%-102.65%37.29%-1.47%-39.63%

Hester Biosciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:16%
5 Years:11%
3 Years:12%
TTM:4%
Compounded Profit Growth
10 Years:8%
5 Years:-14%
3 Years:-20%
TTM:-8%
Stock Price CAGR
10 Years:20%
5 Years:9%
3 Years:0%
1 Year:58%
Return on Equity
10 Years:15%
5 Years:12%
3 Years:11%
Last Year:7%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 11:35 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital9999999999999
Reserves59667693113132169193220251271283293
Borrowings32485559666990121110228274244244
Other Liabilities24192025253532657374116126123
Total Liabilities124142160186213244299387411562670662669
Fixed Assets38546065102110145142133237259240239
CWIP29213336213277410982149171171
Investments00000000021253032
Other Assets5768688589102148170169222237221228
Total Assets124142160186213244299387411562670662669

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +1292019353847375892448
Cash from Investing Activity +-23-15-21-13-30-26-21-73-42-117-77-22
Cash from Financing Activity +1077-72-11319-1811242-26
Net Cash Flow-125-16128-17-23-12-0

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow19.00-10.00-24.00-30.00-25.00-25.00-22.00-22.00-66.00-41.00-168.00-223.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days85757295798767116848610994
Inventory Days7361,145431627376505540834452424399288
Days Payable135145681098410093261204101141101
Cash Conversion Cycle6851,074434614371491514690332409367281
Working Capital Days137194158188145150153169172204203181
ROCE %20%18%15%19%19%20%26%16%18%14%9%9%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%
FIIs0.68%0.80%0.92%0.72%0.62%0.45%0.45%0.45%0.42%0.43%0.43%0.52%
DIIs0.01%0.02%0.03%0.04%0.03%0.03%0.00%0.00%0.00%0.00%0.00%0.00%
Public45.58%45.45%45.31%45.51%45.60%45.77%45.81%45.82%45.84%45.83%45.84%45.74%
No. of Shareholders16,39916,26915,01713,43913,71113,39113,12012,98413,34213,45012,84411,305

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF410.080.01412024-11-100%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)24.8832.9646.4140.7936.44
Diluted EPS (Rs.)24.8832.9646.4140.7936.44
Cash EPS (Rs.)39.6552.1065.4156.4451.81
Book Value[Excl.RevalReserv]/Share (Rs.)356.03339.19314.32277.37242.73
Book Value[Incl.RevalReserv]/Share (Rs.)356.03339.19314.32277.37242.73
Revenue From Operations / Share (Rs.)357.99312.79276.25251.95215.43
PBDIT / Share (Rs.)75.5877.3086.6686.2172.61
PBIT / Share (Rs.)55.3952.9767.1770.5657.24
PBT / Share (Rs.)32.1442.0262.3958.9048.58
Net Profit / Share (Rs.)19.4627.7745.9240.7936.44
NP After MI And SOA / Share (Rs.)22.2031.3046.4140.4734.29
PBDIT Margin (%)21.1124.7131.3734.2133.70
PBIT Margin (%)15.4716.9324.3128.0026.57
PBT Margin (%)8.9713.4322.5823.3722.54
Net Profit Margin (%)5.438.8716.6216.1816.91
NP After MI And SOA Margin (%)6.2010.0016.8016.0615.91
Return on Networth / Equity (%)6.479.5115.1815.0814.50
Return on Capital Employeed (%)8.468.6412.2817.1616.06
Return On Assets (%)2.853.977.028.377.54
Long Term Debt / Equity (X)0.620.660.630.360.38
Total Debt / Equity (X)0.810.950.850.370.54
Asset Turnover Ratio (%)0.450.430.520.620.58
Current Ratio (X)2.031.532.012.631.91
Quick Ratio (X)1.310.961.231.621.14
Inventory Turnover Ratio (X)0.670.660.520.390.49
Dividend Payout Ratio (NP) (%)0.0031.9421.5416.3020.41
Dividend Payout Ratio (CP) (%)0.0017.9715.1711.7614.09
Earning Retention Ratio (%)0.0068.0678.4683.7079.59
Cash Earning Retention Ratio (%)0.0082.0384.8388.2485.91
Interest Coverage Ratio (X)3.257.0618.1411.118.38
Interest Coverage Ratio (Post Tax) (X)1.843.5310.616.765.21
Enterprise Value (Cr.)1416.651555.602514.681703.08877.85
EV / Net Operating Revenue (X)4.655.8510.707.954.79
EV / EBITDA (X)22.0323.6634.1123.2214.21
MarketCap / Net Operating Revenue (X)3.884.869.837.614.29
Retention Ratios (%)0.0068.0578.4583.6979.58
Price / BV (X)4.054.628.887.143.91
Price / Net Operating Revenue (X)3.884.869.837.614.29
EarningsYield0.010.020.010.020.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Hester Biosciences Ltd as of November 15, 2024 is: 2,090.27

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 15, 2024, Hester Biosciences Ltd is Overvalued by 14.93% compared to the current share price 2,457.00

Intrinsic Value of Hester Biosciences Ltd as of November 15, 2024 is: 1,907.84

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 15, 2024, Hester Biosciences Ltd is Overvalued by 22.35% compared to the current share price 2,457.00

Last 5 Year EPS CAGR: -8.73%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 16.92%, which is a positive sign.
  2. The company has higher reserves (170.69 cr) compared to borrowings (126.15 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (153.92 cr) and profit (32.46 cr) over the years.
  1. The stock has a high average Working Capital Days of 171.17, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 432.42, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hester Biosciences Ltd:
    1. Net Profit Margin: 5.43%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 8.46% (Industry Average ROCE: 0.59%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 6.47% (Industry Average ROE: 0.49%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 1.84
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.31
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 89 (Industry average Stock P/E: 0)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.81
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Hester Biosciences Ltd. is a Public Limited Listed company incorporated on 29/04/1987 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L99999GJ1987PLC022333 and registration number is 022333. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 219.35 Cr. and Equity Capital is Rs. 8.51 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals�Pushpak� 1st Floor, Panchvati Circle, Ahmedabad Gujarat 380006mail@hester.in
http://www.hester.in
Management
NamePosition Held
Dr. Bhupendra GandhiChairman
Mr. Rajiv GandhiManaging Director & CEO
Ms. Priya GandhiExecutive Director
Mr. Ravin GandhiDirector
Mr. Sanjiv GandhiDirector
Mr. Ashok BhadakalIndependent Director
Ms. Sandhya PatelIndependent Director
Mr. Ameet DesaiIndependent Director
Mr. Anil JainIndependent Director
Mr. Jatin TrivediIndependent Director
Ms. Nina GandhiAlternate Director

FAQ

What is the latest intrinsic value of Hester Biosciences Ltd?

The latest intrinsic value of Hester Biosciences Ltd as on 15 November 2024 is ₹2090.27, which is 14.93% lower than the current market price of ₹2,457.00.

What is the Market Cap of Hester Biosciences Ltd?

The Market Cap of Hester Biosciences Ltd is 2,090 Cr..

What is the current Stock Price of Hester Biosciences Ltd as on 15 November 2024?

The current stock price of Hester Biosciences Ltd as on 15 November 2024 is ₹2,457.

What is the High / Low of Hester Biosciences Ltd stocks in FY 2024?

In FY 2024, the High / Low of Hester Biosciences Ltd stocks is 3,379/1,293.

What is the Stock P/E of Hester Biosciences Ltd?

The Stock P/E of Hester Biosciences Ltd is 89.0.

What is the Book Value of Hester Biosciences Ltd?

The Book Value of Hester Biosciences Ltd is 355.

What is the Dividend Yield of Hester Biosciences Ltd?

The Dividend Yield of Hester Biosciences Ltd is 0.24 %.

What is the ROCE of Hester Biosciences Ltd?

The ROCE of Hester Biosciences Ltd is 9.32 %.

What is the ROE of Hester Biosciences Ltd?

The ROE of Hester Biosciences Ltd is 6.60 %.

What is the Face Value of Hester Biosciences Ltd?

The Face Value of Hester Biosciences Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Hester Biosciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE